RN7SL165P

Across TCGA pan-cancer cohorts, RN7SL165P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RN7SL165P’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RN7SL165P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL165P is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

HNSC, PAAD, and KIRC are the cancer types where RN7SL165P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL165P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.149	<.001	8	view →
PAAD	Male	All	+0.390	.016	2	view →
KIRC	Female	III,IV	+0.138	.031	2	view →
COAD	All	II,III,IV	−0.088	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RN7SL165P–HNSC

Open the HNSC breakdown →